Background rates, and why they matter for attribution
A small number of serious gastrointestinal events occur in people taking these drugs. Distinguishing them from the expected effect profile is the most consequential…
Side effects
Page 18 of 21 of this archive, newest first.
The eighteenth month, and the conversation that should have happened in the third
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
South Korea pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
Turkey pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The incidence tables, read line by line
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
What the new Sweden guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A schedule that bends does not break
Every major phase 3 protocol in this class allowed escalation to be delayed for tolerability. Almost no product label explains the mechanics of doing so.
The mechanism behind the mechanism
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Ireland pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Spain pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Tolerability is the ceiling, and the ceiling is personal
The ceiling varies severalfold between people, and nothing measurable at baseline predicts where it sits.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Holidays, surgery, sickness: interruption in practice
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
What a month without the drug does to tolerability
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
What the trials adjudicated, and how
The features that should prompt urgent assessment, stated once and plainly.